Mandate

Vinge advises consortium led by Advent International on acquisition of Hoist Group Holding Intressenter AB (publ)

Vinge together with Weil, Gotshal & Manges LLP is advising a consortium led by Advent International in connection with its acquisition of Hoist Group Holding Intressenter AB (publ) (the ”Hoist Group”).

Hoist Group provides technology solutions to hotels, enabling them to manage coherent end-to-end digital journeys for their guests. Hoist Group optimizes guest services by correlating and analyzing the data that comes from its innovative Property Management & Booking Software, Managed IP Networks, Internet and TV Content as well as from many other digital touchpoints. Headquartered in Stockholm with 20 offices across EMEA, Hoist Group has nearly 500 dedicated staff serving over 8,000 unique hotels.

The sale is subject to standard regulatory approval, among other things, and is expected to be completed in the second half of 2021. In France, the agreement is subject to completion of French works council consultations.

The Vinge team advising Advent International includes partners Daniel Rosvall, Henrik Borna and Anna Edström, counsel Emelie Svensäter Jerntorp and associates Carl Sander and Viktor Lennartsson. Counsel Fredrik Christiansson advises on financing matters

 

Related

Vinge has advised Verisure in connection with its IPO on Nasdaq Stockholm

Vinge has advised Verisure plc (“Verisure”) in connection with its IPO on Nasdaq Stockholm. Following the publication of the prospectus on 29 September 2025, trading in Verisure’s shares commenced today, 8 October 2025.
October 08, 2025

Vinge has acted for Advania on the acquisition of smartvokat

smartvokat GmbH, a German-based consultancy specialising in digital transformation within the legal, risk, and compliance domains, will become part of Advania’s business unit Transformation & Automation.
October 08, 2025

Vinge has advised Egetis Therapeutics in connection with a directed share issue

Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025